Clinical Trials in San Francisco

Showing 10321-10340 of 12,991 trials

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679

To compare the pharmacodynamic effects of 2 continuous dose regimens of ulipristal acetate 5.0 and 10.0 mg-only oral contraception, versus a 24/4 day regimen of UPA 5.0 mg.

Focus: Estrogen-free Oral Contraception

Premier Research180 participantsStarted Mar 2014

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +7 more locations

COMPLETEDNA< 1 mile

GORE Flow Reversal System and GORE Embolic Filter Extension Study

NCT01343667

The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.

Carotid StenosisConstriction, PathologicCarotid Artery Diseases+8 more

W.L.Gore & Associates1,397 participantsStarted Apr 2011

Flagstaff, Arizona, United States • Newport Beach, California, United States • San Francisco, California, United States +36 more locations

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Find Trials by Condition in San Francisco

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Imatinib (QTI571) in Pulmonary Arterial Hypertension

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Blood and Marrow Transplant Clinical Research Network

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Relapse Prevention Study in Newly Abstinent Smokers

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)

Atacicept in Subjects With Optic Neuritis